Exhibit 99.1 Certara Reports Third Quarter 2024 Financial Results Updates Full Year 2024 Financial Guidance RADNOR, PA — November 6, 2024-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: • Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. • Software revenue was $35.9 million, compared to $31.3 million in the ...

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth of 15%.Services revenue was $58.9 million, compared to ...

RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference. Company management will present at 10:00AM CT on Thursday, November 21st, 2024. A live webcast of the event will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About Certara Certara ...

RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense val ...

RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A ...

RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon. Chemaxon develops leading scientific informatics software products used by the life sciences industry for insilico research. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules. "Combining Chemaxon's expertise with ...

Core Insights - Certara, Inc. collaborated with Ichnos Glenmark Innovation (IGI) to optimize the first-in-human (FIH) dose for ISB 2001, a trispecific T-cell engager aimed at treating relapsed/refractory multiple myeloma, with results published in Nature Cancer [1][2] Group 1: Collaboration and Innovation - The collaboration focused on developing a virtual clinical trial platform using quantitative systems pharmacology (QSP) and physiologically-based pharmacokinetics (PBPK) to enhance FIH dose selection [2][3] - The innovative approach allowed for a clinical starting dose increase of approximately 50-100 fold compared to conventional methods, reducing the risk of ineffective dosing for cancer patients [3][4] Group 2: Efficiency and Regulatory Alignment - Utilizing virtual trials for dose optimization not only saves time and costs but also aligns with regulatory goals, minimizing the need for animal studies in drug development [4][5] - The approach has been accepted by the U.S. FDA and Australian HREC, setting a precedent for determining FIH dosing for ISB 2001 and other T-cell engagers [3][4] Group 3: Company Background - Certara specializes in biosimulation software and services, serving over 2,400 clients in the biopharmaceutical sector across 66 countries, aiming to transform traditional drug discovery and development processes [6]

RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Date and Time: Wednesday, September 4 at 4:05 p.m. ET Baird Global Healthcare Conference Date and Time: Wednesday, September 11 at 10:15 a.m. ET Live webcasts for each of the conferences will be available on Certara's investor rela ...

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical industry's gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. The Phoenix Platform is used by more than 75 of the top 100 pharmaceutical companies worldwide. Eleven regulatory agencies, including the U.S. FDA, Japan PMDA, and China NMPA, rely ...

Certara, Inc. (NASDAQ:CERT) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens David Windley - Jefferies Dan Clark - Leerink Partners Joe Vruwink - Baird Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara Second Quarter 2024 Earnings Conference Ca ...